

01-93000-05

Original Effective Date: 11/15/01

Reviewed: 12/04/25

Revised: 12/15/25

Subject: Cardiac Monitoring Devices

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

Position Statement	Billing/Coding	Reimbursement	Program Exceptions	Definitions	Related Guidelines
Other	References	Updates			

DESCRIPTION:

Various devices are available for outpatient cardiac rhythm monitoring. These devices differ in the types of monitoring leads used, the duration and continuity of monitoring, the ability to detect arrhythmias without patient intervention, and the mechanism of delivering the information from patient to clinician. These devices may be used to evaluate symptoms suggestive of arrhythmias (eg, syncope, palpitations), and may be used to detect atrial fibrillation (AF) in patients who have undergone cardiac ablation of AF or who have a history of cryptogenic stroke.

Ambulatory event monitors (AEMs) were developed to provide longer periods of monitoring. In this technique the recording device is worn continuously and activated only when the patient experiences symptoms or is carried by the patient and applied and activated when symptoms are present. The recorded EKGs are then stored for future analysis or transmitted by telephone to a receiving station, e.g., a doctor's office, hospital, or cardiac monitoring service, where the EKGs can then be analyzed. AEMs can be used for extended periods of time, typically up to a month until the patient experiences symptoms. Since the EKGs are recorded only during symptoms, there is good correlation with any underlying arrhythmia. Conversely, if no EKG abnormality is noted, a noncardiac etiology of the patient's symptoms can be sought.

Real-time Continuous Attended Remote Cardiac Monitoring Systems: Unlike ambulatory event monitors that store the recorded data, which are ultimately transmitted either to a physician's office or to a central recording station, real-time continuous attended remote cardiac monitoring systems automatically record and transmit arrhythmia event data from the patient to a qualified healthcare professional attending the monitor at a clinic or hospital. These systems allow automatic wireless transmission of abnormal ECG waveforms from the patient's home to an attended monitoring center at the time of the arrhythmia event.

Omnicardiogram/Cardiointegram (CIG): An omnicardiogram/cardiointegram device consists of a microcomputer, which receives output from a standard electrocardiogram (ECG) and transforms it to produce a graphic representation of heart electrophysiologic signals. This procedure is used primarily as a substitute for Exercise Tolerance Testing with Thallium Imaging in patients for whom a resting ECG may be inadequate to identify changes compatible with coronary artery disease.

Implantable Pulmonary Artery Pressure Sensor Devices: The FDA approved the CardioMEMS™ Heart Failure Monitoring System through the premarket approval (PMA) process in 2014. The device consists of an implantable sensor, which is implanted in the distal pulmonary artery (PA), a transvenous delivery system, and an electronic sensor that processes signals from the implantable PA sensor and transmits PA pressure measurements to a secure database. Several other devices that monitor cardiac output by measuring pressure changes in the pulmonary artery or right ventricular outflow tract have been investigated in the research setting but have not received FDA approval.

Summary and Analysis of Evidence: Patients with signs and/or symptoms suggestive of arrhythmia(s) who receive patient- or auto-activated external ambulatory event monitoring or continuous ambulatory monitoring storing information for more than 48 hours, the evidence includes prospective and retrospective studies reporting on the diagnostic yield. Observational studies have consistently shown that continuous monitoring with longer recording periods detects more arrhythmias than 24- or 48-hour Holter monitoring. Particularly for patients who, without the more prolonged monitoring, would only undergo shorter term monitoring, the diagnostic yield is likely to identify arrhythmias that may have therapeutic implications. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome. Patients with AF following ablation who receive long-term ambulatory cardiac monitoring, the evidence includes one randomized controlled trial (RCT) comparing ambulatory event monitoring with standard care and several observational studies. The available evidence has suggested that long-term monitoring for AF postablation is associated with improved outcomes. However, the specific type of monitoring associated with the best outcomes is not established, because different long-term monitoring devices were used across the studies. Trials demonstrating improved outcomes have used event monitors or implantable monitors. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome. Patients who had a cryptogenic stroke with a negative standard workup for AF and receive long-term ambulatory cardiac monitoring, the evidence includes systematic reviews of RCTs comparing ambulatory event monitoring with standard care. The available evidence has suggested that long-term monitoring for AF after cryptogenic stroke is associated with improved outcomes, but the specific type of monitoring associated with the best outcomes is not established because different long-term monitoring devices were used across the studies. Trials demonstrating improved outcomes have used event monitors or implantable monitors. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome. Asymptomatic patients with risk factors for AF who receive long-term ambulatory cardiac monitoring, the evidence includes RCTs and observational studies. Multiple observational studies showed that the use of ambulatory monitors would result in higher AF detection compared with routine care. Randomized controlled trials found higher AF detection and initiation of anticoagulants with monitoring, but no impact on health outcomes. The only RCT (LOOP Trial) with sufficient statistical power and duration to evaluate health outcomes found no difference between monitoring and standard care on the primary endpoint of combined stroke or systemic arterial embolism (HR 0.80; 95% CI 0.61 to 1.05; P = .11) or any secondary endpoints after 6 years of follow-up.

The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. Patients with signs and/or symptoms suggestive of arrhythmia with infrequent symptoms who receive patient- or auto-activated implantable ambulatory event monitoring, the evidence includes RCTs comparing implantable loop recordings (ILRs) with shorter term monitoring, usually 24- to 48-hour Holter monitoring, and many observational studies. Studies assessing prolonged ILRs in patients have reported high rates of arrhythmia detection compared with shorter external event or Holter monitoring. These studies have supported use of a progression in diagnostics from an external event monitor to ILR when longer monitoring is needed. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome. Patients with signs and/or symptoms suggestive of arrhythmia who receive outpatient cardiac telemetry, the evidence includes an RCT and nonrandomized studies evaluating rates of arrhythmia detection using outpatient cardiac telemetry. The available evidence has suggested that outpatient cardiac telemetry is at least as good at detecting arrhythmias as ambulatory event monitoring. However, studies have not evaluated whether the real-time monitoring feature of outpatient cardiac telemetry leads to reduced cardiac events and mortality. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

POSITION STATEMENT:

The use of patient-activated or auto-activated (i.e., auto-triggered) external ambulatory event monitors or continuous ambulatory monitors that record and store information for periods longer than 48 hours **meets the definition of medical necessity** as a diagnostic alternative to Holter monitoring in the following situations:

- Members who experience infrequent symptoms (less frequently than every 48 hours) suggestive of cardiac arrhythmias (i.e., palpitations, dizziness, presyncope, or syncope);
- Members with atrial fibrillation who have been treated with catheter ablation, and in whom discontinuation of systemic anticoagulation is being considered; **OR**
- Members with cryptogenic stroke who have a negative standard work-up for atrial fibrillation including a 24-hour Holter monitor.

The use of implantable ambulatory event monitors, either patient-activated or auto-activated, **meets the definition of medical necessity** in the following situations:

- In the small subset of members who experience recurrent symptoms so infrequently that a prior trial of other external ambulatory event monitors has been unsuccessful; **OR**
- In members who require long-term monitoring for atrial fibrillation or possible atrial fibrillation.

The use of mobile cardiac outpatient telemetry (MCOT) (also known as outpatient cardiac telemetry or mobile cardiovascular telemetry/MCT) **meets the definition of medical necessity** when the following criteria are met:

- The member has had a previous (within the last 60 days) non-diagnostic trial of external ambulatory event monitoring; **AND**
- The member has **ONE** of the following:
 1. A history of cryptogenic stroke; or

2. Recurrent, unexplained episodes of syncope or presyncope of suspected arrhythmic etiology.

The use of mobile cardiac outpatient telemetry (MCOT) **does not meet the definition of medical necessity** for all other indications including, but not limited to, ongoing management after diagnosis, medication management, screening, or monitoring members with life-threatening arrhythmias.

Other uses of ambulatory event monitors, including mobile applications, are considered **experimental or investigational**, including but not limited to monitoring asymptomatic members with risk factors for arrhythmia, monitoring the effectiveness of antiarrhythmic medications, and detection of myocardial ischemia by detecting ST-segment changes. The evidence is insufficient to determine the effects of the technology on health outcomes.

Omnicardiogram/Cardiointegram (CIG), a technique intended to detect abnormalities in the standard 12-lead electrocardiogram that are beyond the standard, routine interpretation in members at risk of risk of cardiac ischemia, is considered **experimental or investigational**. There is insufficient evidence to support conclusions regarding its efficacy, sensitivity and value as a diagnostic tool.

The use of implantable pulmonary artery pressure sensor devices (i.e. CardioMEMS™ HF Monitoring System) in the ambulatory care and outpatient setting is considered **experimental or investigational** for all indications. The evidence is insufficient to determine the effects of the technology on health outcomes.

BILLING/CODING INFORMATION:

CPT Coding:

33285	Insertion, subcutaneous cardiac rhythm monitor, including programming
33286	Removal, subcutaneous cardiac rhythm monitor
33289	Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed (Investigational)
93228	External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional
93229	External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; technical support for connection and patient instructions for use, attended surveillance, analysis and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional

93241	External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation
93242	External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; recording (includes connection and initial recording)
93243	External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; recording (includes connection and initial recording)
93244	External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation
93245	External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation
93246	External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)
93247	External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; scanning analysis with report
93248	External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation
93264	Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional (Investigational)
93268	External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; includes transmission, review and interpretation by a physician or other qualified health care professional
93270	External patient electrocardiographic rhythm derived event recording with pre-symptom memory loop, 24-hour attended monitoring, per 30-day period of time; recording (includes connection, recording, and disconnection)
93271	External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; transmissions, and analysis
93272	External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; review and interpretation by a physician or other qualified health care professional

HCPCS Coding:

E0616	Implantable cardiac event recorder with memory, activator and programmer
G0555	Provision of replacement patient electronics system (e.g., system pillow, handheld reader) for home pulmonary artery pressure monitoring (Investigational)

S9025	Omnicardiogram/cardiointegram (Investigational)
-------	--

ICD-10 Diagnosis Codes That Support Medical Necessity for codes 33285, 33286, 93241-93248, 93268, 93270, 93271, 93272, and E0616:

I44.0 – I44.7	Atrioventricular and left bundle-branch block
I45.0 – I45.9	Other conduction disorders
I47.0 – I47.9	Paroxysmal tachycardia
I48.0 – I48.19	Atrial fibrillation and flutter
I49.01 – I49.9	Other cardiac arrhythmias
I63.9	Cerebral infarction, unspecified
R00.2	Palpitations
R42	Dizziness and giddiness
R55	Syncope and collapse

ICD-10 Diagnosis Codes That Support Medical Necessity for codes 93228 and 93229:

I63.9	Cerebral infarction, unspecified
I69.30-I69.398	Sequelae of cerebral infarction
R42	Dizziness and giddiness
R55	Syncope and collapse
Z86.73	Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits

LOINC Codes:

The following information may be required documentation to support medical necessity: physician history and physical, conservative treatment plan, physician progress notes, and all laboratory studies.

Documentation Table	LOINC Codes	LOINC Time Frame Modifier Code	LOINC Time Frame Modifier Codes Narrative
Physician history and physical	28626-0,	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Attending physician progress note	18741-9	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Medication Current	19009-0	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.

Current, Discharge, or administered medications	34483-8	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
---	---------	---------	--

REIMBURSEMENT INFORMATION:

Refer to sections entitled [POSITION STATEMENT](#)

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage products:

The following national coverage Determinations (NCDs) were reviewed on the last guideline reviewed date and are located at cms.gov: Electrocardiographic Services (20.15), Implantable Pulmonary Artery Pressure Sensors for Heart Failure Management (20.36), and Cardiointegram (CIG) as an Alternative to Stress Test or Thallium Stress Test (20.27).

The following are located at fcso.com: Local Coverage Determination (LCD) Ambulatory Electrocardiograph (AECG) Monitoring L39492; and Local Coverage Article Billing and Coding: Ambulatory Electrocardiograph (AECG) Monitoring A59270.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#)

DEFINITIONS:

None applicable.

RELATED GUIDELINES:

None applicable.

OTHER:

None applicable.

REFERENCES:

1. Abraham WT, et al; Sustained Efficacy of Pulmonary Artery Pressure To Guide Adjustment of Chronic Heart Failure Therapy: Complete Follow-Up Results from the CHAMPION Trial. Lancet. 2016 Jan 30;387(10017):453-61.

2. Adamson PB, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. *Circ Heart Fail* 2014 Nov;7(6):935-44.
3. Agency for Healthcare Research and Quality (AHRQ), Technology Assessment Program- Remote Cardiac Program, 12/12/07; accessed at [cms.gov](https://www.cms.gov).
4. American College of Cardiology – Ambulatory External Electrocardiographic Monitoring; Focus on Atrial Fibrillation. Suneet Mittal, MD, Colin Movsowitz, MBCHB, Jonathan S. Steinberg, MD. *JACC* Vol. 58, No. 17, 2011. October 18, 2011:1741–9.
5. Angermann CE, Assmus B, et al. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). *Eur J Heart Fail*. 2020 Oct;22(10):1891-1901.
6. Bhimaraj A, Benjamin TA, et al. Translating Pressure into Practice: Operational Characteristics of Ambulatory Hemodynamic Monitoring Program in the United States. *J Card Fail*. 2023 Jun 14;S1071-9164(23)00201-4. PMID: 37328050.
7. Blue Cross Blue Shield Association Evidence Positioning System®. 2.02.08 Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry, 11/25.
8. Blue Cross Blue Shield Association Evidence Positioning System®. 2.02.24 Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting, 07/25.
9. Brugts JJ, Radhoe SP, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomized clinical trial. *Lancet*. 2023 May 19;S0140-6736(23)00923-6.
10. Centers for Medicare and Medicaid Services (CMS), National Coverage Determination (NCD) Electrocardiographic Services (20.15); accessed at [cms.gov](https://www.cms.gov).
11. Centers for Medicare and Medicaid Services (CMS), National Coverage Determination (NCD) Cardiointegram (CIG) as an Alternative to Stress Test or Thallium Stress Test (20.27); accessed at [cms.gov](https://www.cms.gov).
12. Centers for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD) Implantable Pulmonary Artery Pressure Sensors for Heart Failure Management (20.36); accessed at [cms.gov](https://www.cms.gov).
13. Ciotola F, Pyxaras S, et al. MEMS Technology in Cardiology: Advancements and Applications in Heart Failure Management Focusing on the CardioMEMS Device. *Sensors (Basel)*. 2024 May 3;24(9):2922. doi: 10.3390/s24092922.
14. Clephas PR, Aydin D, et al. Recent Advances in Remote Pulmonary Artery Pressure Monitoring for Patients with Chronic Heart Failure: Current Evidence and Future Perspectives. *Sensors (Basel)*. 2023 Jan 26;23(3):1364.
15. [ClinicalTrials.gov](https://clinicaltrials.gov). CardioMEMS HF System OUS Post Market Study; accessed June 2023.
16. [ClinicalTrials.gov](https://clinicaltrials.gov). Patient SELF-management With Hemodynamic Monitoring: Virtual Heart Failure Clinic and Outcomes (the SELFle-HF Trial); accessed June 2023.
17. [ClinicalTrials.gov](https://clinicaltrials.gov). Pulmonary Artery Sensor System Pressure Monitoring to Improve Heart Failure (HF) Outcomes; accessed June 2023.
18. Cowie MR, Flett A, et al. Real-world evidence in a national health service: results of the UK CardioMEMSHF System Post-Market Study. *ESC Heart Fail*. 2022 Feb; 9(1): 48–56.
19. Crawford MH, Bernstein SJ, et al. ACC/AHA guidelines for ambulatory electrocardiography: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). *Circulation*. 1999; 100:886-893.

20. Culebras A, Messe SR, Chaturvedi S, et al. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2014 Feb 25;82(8):716-24.
21. DeFilippis EM, Henderson J, et al. Remote Hemodynamic Monitoring Equally Reduces Heart Failure Hospitalizations in Women and Men in Clinical Practice: A Sex-Specific Analysis of the CardioMEMS Post-Approval Study. *Circ Heart Fail*. 2021 Jun;14(6):e007892. PMID:34129363.
22. Derkac WM, Finkelmeier JR, et al. Diagnostic yield of asymptomatic arrhythmias detected by mobile cardiac outpatient telemetry and autotrigger looping event cardiac monitors. *J Cardiovasc Electrophysiol*. 2017 Dec;28(12):1475-1478.
23. Dickinson MG, Allen LA, Albert NA, et al. Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee. *J Card Fail*. 2018 Oct;24(10):682-694. Doi: 10.1016/j.cardfail.2018.08.011. Epub 2018 Oct 9. PMID: 30308242.
24. Dorr M, Nohturfft V, et al. The WATCH AF Trial: SmartWATCHes for Detection of Atrial Fibrillation. *JACC ClinElectrophysiol*. Feb 2019; 5(2): 199-208. PMID 30784691.
25. Eysenck W, Freemantle N, Sulke N. A Randomized Trial Evaluating the Accuracy of AF Detection by Four External Ambulatory ECG Monitors Compared to Permanent Pacemaker AF Detection *J Interv Card Electrophysiol*. Apr 2020; 57(3): 361-369. PMID 30741360.
26. Farris GR, Smith BG, et al. New Atrial Fibrillation Diagnosed by 30-day Rhythm Monitoring *Am Heart J*. Mar 2019;209: 29-35. PMID 30639611.
27. First Coast Service Options, Inc. (FCSO). Local Coverage Article Billing and Coding: Ambulatory Electrocardiograph (AECG) Monitoring A59270; accessed at fcso.com.
28. First Coast Service Options, Inc. (FCSO). Local Coverage Determination (LCD) Ambulatory Electrocardiograph (AECG) Monitoring L39492; accessed at fcso.com.
29. Garg T, Raikhelkar J, et al. Large pulmonary artery pseudoaneurysm after CardioMEMS implantation: a case report. *Eur Heart J Case Rep*. 2022 Mar 22;6(4):ytac113.
30. Gill J. Implantable cardiovascular devices: current and emerging technologies for remote heart failure monitoring. *Cardiol Rev*. 2022 Jan 21. PMID: 35349243.
31. Heidenreich PA, Bozkurt B, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. May 03 2022; 145(18): e895-e1032.
32. Heywood JT, Zalawadiya S, et al. Sustained Reduction in Pulmonary Artery Pressures and Hospitalizations During 2 Years of Ambulatory Monitoring. *J Card Fail*. 2023 Jan;29(1):56-66. PMID: 36332900.
33. Ho C. Implantable hemodynamic monitoring (the Chronicle IHM system): remote telemonitoring for patients with heart failure. *Issues Emerg Health Technol*. 2008 Jan;(111):1-4. [PubMed ID18354860].
34. Ho JS, Ho ES, et al. Use of wearable technology in cardiac monitoring after cryptogenic stroke or embolic stroke of undetermined source: a systematic review. *Singapore Med J*. 2024 Jul 1;65(7):370-379. doi: 10.4103/singaporemedj.SMJ-2022-143.
35. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm*. 2019 Jan 28. Pii: S1547-5271(19)30037-2.
36. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2014 Dec 2;64(21):e1-76.

37. Joglar JA, Chung MK, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2024 Jan 2;83(1):109-279. doi: 10.1016/j.jacc.2023.08.017.
38. Joshi AK, Kowey PR, et al. First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia. *Am J Cardiol*. 2005 Apr 1; 95(7): 878-81.
39. Katapadi A, Chelikam N, et al. Dynamic data-driven management of atrial fibrillation with implantable cardiac monitors: The MONITOR AF study. *Heart Rhythm*. 2025 Jan 16:S1547-5271(25)00025-6. doi: 10.1016/j.hrthm.2025.01.011. PMID: 39826639.
40. Kaura A, Sztriha L, et al. Early Prolonged Ambulatory Cardiac Monitoring in Stroke (EPACS): An Open-Label Randomised Controlled Trial *Eur J Med Res*. Jul 26 2019; 24(1): 25. PMID 31349792.
41. Krahnke JS, et al. Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. *J Cardiac Fail* 2015;21(3):240-9.
42. Kwaku KF. Cardiac implantable electronic devices: Periprocedural complications – UpToDate. Piccini J, Parikh N (Eds); accessed June 2023 at uptodate.com.
43. Langén V, Winstén AK, et al. Clinical outcomes of atrial fibrillation screening: a meta-analysis of randomized controlled trials. *Ann Med*. 2025 Dec;57(1):2457522. doi: 10.1080/07853890.2025.2457522.
44. Lin AL, Hu G, et al. Quantification of Device-Related Event Reports Associated With the CardioMEMS Heart Failure System. *Circ Cardiovasc Qual Outcomes*. 2022 Oct;15(10):e009116.
45. Lindenfeld J, Zile MR, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomized controlled trial. *Lancet*. 2021 Sep 11;398(10304):991-1001.
46. Lopes RD, Atlas SJ, et al. Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention. *J Am Coll Cardiol*. 2024 Nov 19;84(21):2073-2084. doi: 10.1016/j.jacc.2024.08.019. PMID: 39230544.
47. Mehall JR, Kohut RM Jr, et al.. Absence of correlation between symptoms and rhythm in “symptomatic” atrial fibrillation. *Ann Thorac Surg*. 2007 Jun; 83(6): 2118-21.
48. Mullis AH, Ayoub K, et al. Fluctuations in Premature Ventricular Contraction Burden Can Affect Medical Assessment and Management *Heart Rhythm*. Oct 2019; 16(10): 1570-1574. PMID 31004780.
49. Murphy R, Waters, R, et al. Risk-based screening for the evaluation of atrial fibrillation in general practice (R-BEAT): a randomized cross-over trial. *QJM*. 2025 Mar 1;118(3):166-173. doi: 10.1093/qjmed/hcaf001.
50. Ng E, Stafford PJ, Ng GA. Arrhythmia detection by patient and auto-activation in implantable loop recorders. *J Interv Card Electrophysiol*. 2004 Apr; 10(2): 147-52.
51. Olson JA, Fouts AM, Padanilam BJ, Prystowsky EN. Utility of mobile cardiac outpatient telemetry for the diagnosis of palpitations, presyncope, syncope, and the assessment of therapy efficacy. *J Cardiovasc Electrophysiol*. 2007 May; 18(5): 473-7. Epub 2007 Mar 6.
52. Ponikowski P, et al, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2016 May 20. Doi: 10.1002/ehf.592.
53. Prystowsky EN. Assessment of rhythm and rate control in patients with atrial fibrillation. *J Cardiovasc Electrophysiol*. 2006 Sep; 17 Suppl 2:S7-S10.

54. Radhoe SP, Clephas PR, et al. The CardioMEMS Heart Failure System for chronic heart failure – a European perspective. *Expert Rev Med Devices*. 2023 May;20(5):349-356. PMID: 37070597.
55. Raviele A et al. Management of patients with palpitations: A position paper from the European Heart Rhythm Association. *Europace* 2011 Jul;13(7):920-934.
56. Rothman SA, Laughlin JC, et al. The diagnosis of cardiac arrhythmias: a prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring. *J Cardiovasc Electrophysiol*. 2007 Mar; 18(3): 241-7.
57. Saarel EV, Doratotaj S, Sterba R. Initial experience with novel mobile cardiac outpatient telemetry for children and adolescents with suspected arrhythmia. *Congenit Heart Dis*. 2008 Jan;3(1):33-8 [PubMed ID 18373747].
58. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. Aug 1 2017;70(5):620-663.
59. Smith EE, Saposnik G, Biessels GJ, et al. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2017 Feb;48(2):e44-e71.
60. Steinberg JS, Varma N, Cygankiewicz I, et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. *Heart Rhythm*. Jul 2017;14(7):e55-e96.
61. Stork S, Bernhardt A, et al. Pulmonary artery sensor system pressure monitoring to improve heart failure outcomes (PASSPORT-HF): rationale and design of the PASSPORT-HF multicenter randomized clinical trial. *Clin Res Cardiol*. 2022 Mar 4;1-11.
62. Strickberger SA, Benson DW, et al. AHA/ACCF Scientific Statement on the Evaluation of Syncope: From the American heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and The Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation in Collaboration with the Heart Rhythm Society. *J Am Coll Cardiol*. 2006; 47; 473-484.
63. Tayal AH, Tian M, et al. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. *Neurology* 2008 Nov 18;71(21):1696-701 [PubMed ID 18815386].
64. Tsang JP, Mohan S, Benefits of monitoring patients with mobile cardiac telemetry (MCT) compared with the Event or Holter monitors, *Med Devices (Auckl)*. 2014; 7:1-5; published online 2013 Dec 9.
65. U.S. Food and Drug Administration (FDA); accessed at [fda.gov](https://www.fda.gov).
66. U.S. Preventive Services Task Force (USPSTF). Atrial Fibrillation: Screening, 01/25/22; accessed at [uspreventiveservicestaskforce.org](https://www.uspreventiveservicestaskforce.org).
67. Vasamreddy CR, Dalal D, et al. Symptomatic and asymptomatic atrial fibrillation in patients undergoing radiofrequency catheter ablation. *J Cardiovasc Electrophysiol*. 2006 Feb; 17(2): 134-9.
68. Visco V, Esposito C, et al. A Multistep Approach to Deal With Advanced Heart Failure: A Case Report on the Positive Effect of Cardiac Contractility Modulation Therapy on Pulmonary Pressure Measured by CardioMEMS. *Front Cardiovasc Med*. 2022 Apr 4;9:874433.
69. Wineinger NE, Barrett PM, et al. Identification of Paroxysmal Atrial Fibrillation Subtypes in Over 13,000 Individuals *Heart Rhythm*. Jan 2019; 16(1): 26-30. PMID 30118885.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 12/04/25.

GUIDELINE UPDATE INFORMATION:

11/15/01	Medical Coverage Guideline Reformatted.
01/01/02	HCPCS coding changes.
01/01/03	HCPCS coding changes.
03/15/03	Reviewed; no changes.
03/15/04	Review and revision of guideline consisting of updating references, adding description and coverage criteria for implantable loop recorder, and converting MCG to “Guideline No Longer Scheduled For Routine Review”. Also changed the title to “Ambulatory Event Monitors”.
04/01/06	HCPCS coding update consisting of the addition of S0345-S0347 and investigational statement for outpatient cardiac telemetry.
06/15/07	Review and revision of guideline consisting of updated references and reformatted guideline.
07/15/08	Review and revision of guideline consisting of updated references.
01/01/09	Annual HCPCS coding update: added codes 93228, 93229, 93285, 93291, 93298 and 93299. Revised codes 93268, 93270, 93271 and 93272. Deleted code 93277.
09/15/09	Scheduled review; no change to position statement; references updated.
01/01/10	Annual HCPCS coding update: revised descriptor for 93285; deleted S0345, S0346, and S0347.
08/15/10	Scheduled review; position statement unchanged; references updated.
01/01/11	Revision; Annual HCPCS coding update: revised descriptors for 93228, 93229, 93268, 93270, 93271, and 93272; related ICD-10 codes added; formatting changes.
08/15/11	Annual review; position statement unchanged; references updated; formatting changes.
09/15/11	Revision; formatting changes.
01/01/12	Annual HCPCS coding update: revised code descriptor for 93271.
03/15/11	Scheduled review; position statement unchanged; CPT codes 0295T – 0298T added; references updated.
09/01/12	Revision: updated billing and coding section to add coding instructions and remove deleted codes 93012 and 93014.
01/01/13	Annual HCPCS coding update: revised descriptors for 93228, 93229, 93268, 93272, 93285, 93291, and 93298.
03/15/13	Scheduled review; position statement unchanged; Program Exception added for Medicare Advantage products; references updated.
07/15/14	Scheduled review; position statement unchanged; Program Exception section updated; references updated.
09/15/15	Revision; guideline title, description section, position statement, program exception, and references updated; formatting changes.
11/01/15	Revision: ICD-9 Codes deleted.
09/15/16	Revision; description, position statements, coding/billing, and references updated; formatting changes.
01/01/18	Annual CPT/HCPCS update. Added codes 0497T and 0498T.
08/15/18	Revision; Position statements, description, coding, and references updated.
10/01/18	Program exception and references updated.

01/01/19	Annual CPT/HCPCS coding update. Added codes 33285-33289, 93264; deleted codes 33282 & 33284.
07/15/19	Review; MCOT position statements, coding, and references updated.
10/01/19	Annual ICD-10 update. Revised I48 code range.
07/15/20	Review; Maintain position statements and update references.
01/01/21	Annual CPT/HCPCS update. Codes 93241-93248 added; codes 0295T-0298T deleted.
09/15/22	Review: Position statements, description and references updated.
01/01/23	Annual CPT/HCPCS update. Codes 0497T and 0498T deleted.
05/22/23	Update to Program Exceptions section.
08/15/23	Review: Position statements maintained and references updated.
01/01/24	Program exemption and references updated.
01/01/25	Annual CPT/HCPCS coding update. Code G0555 added.
12/15/25	Review: Position statements maintained; description and references updated.